Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2024-03-12 Capital/Financing Update
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Memorandum of Understanding/Agreements
Capital/Financing Update Classification · 95% confidence The document is a formal notification addressed to stock exchanges regarding the acquisition of land by the company. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details of the transaction in an annexure. The content is an announcement of a corporate event (land acquisition) rather than a financial report, management discussion, or regulatory certification. The document length is under 5,000 characters and it is a direct announcement of a material event related to the company’s operations and asset acquisition. This fits best under the category of Capital/Financing Update (CAP), as it relates to a significant capital asset acquisition and expansion plans disclosed to the market.
2024-03-12 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges (National Stock Exchange of India Limited and Bombay Stock Exchange Limited) regarding the commencement of commercial production by a wholly owned subsidiary of the company. It includes a press release announcing this operational update. The document is short (3752 characters) and primarily serves as an announcement of a business event rather than a financial report or detailed regulatory filing. It does not contain financial statements, voting results, management changes, or other report types defined in the filing categories. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into more specific categories such as earnings release, capital update, or management information.
2024-03-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 85% confidence The document is a letter addressed to stock exchanges informing them about the schedule of an analyst/institutional investor meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is about notifying the schedule of an investor conference and does not contain any financial data, results, or detailed presentations. It is essentially an announcement of an upcoming investor meeting rather than the meeting materials or transcript itself. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to investor meetings and presentations, but since it only announces the schedule and does not provide the presentation itself, it is more appropriate to classify it as Regulatory Filings (RNS) as a general regulatory announcement. However, given the specific nature of the announcement about an investor meeting schedule, the closest specific category is Investor Presentation (IP) because it relates to investor communication events. Confidence is high due to clear mention of investor meeting schedule and no financial data or report attached.
2024-02-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges about the schedule of an analyst/institutional investor meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events and information. The content is an intimation about a future meeting with analysts/investors, specifying date, participants, and mode of interaction. There is no financial data, no report attached or published, and no detailed presentation or results disclosed. This type of document is a regulatory announcement informing the market about an upcoming investor interaction, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories like Investor Presentation or Earnings Release. The document length is short and it is not a report or presentation itself.
2024-02-01 English
Updates
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) regarding a corporate guarantee extended by the company to its wholly owned subsidiary. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to continuous disclosures about material events. The content is an announcement of a corporate guarantee approval by the executive committee, including details of the guarantee and its impact as a contingent liability. The document is relatively short (3187 characters) and does not contain financial statements or detailed financial analysis. It is an update on a financing-related event but not a full capital/financing report. This fits best under Capital/Financing Update (CAP) as it relates to corporate guarantee disclosures impacting the company's capital structure and contingent liabilities.
2024-01-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held on January 23, 2024, discussing the unaudited financial results for the quarter and nine months ended December 31, 2023. It includes detailed management commentary, financial highlights, and a Q&A session with analysts. The presence of forward-looking statements, detailed financial data, and management discussion confirms this is a full transcript of the earnings call rather than a brief earnings release or summary. Therefore, the document fits the definition of a Call Transcript (CT).
2024-01-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.